AVCTF Stock - Avacta Group Plc
Unlock GoAI Insights for AVCTF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $113,000 | $23.25M | $9.65M | $2.94M | $3.64M |
| Gross Profit | $113,000 | $7.57M | $7.24M | $2.02M | $2.18M |
| Gross Margin | 100.0% | 32.6% | 75.0% | 68.6% | 60.0% |
| Operating Income | $-32,558,000 | $-26,717,000 | $-32,645,000 | $-29,083,000 | $-21,293,000 |
| Net Income | $-52,841,000 | $-24,947,000 | $-39,189,000 | $-26,316,000 | $-18,891,000 |
| Net Margin | -46761.9% | -107.3% | -406.0% | -894.8% | -519.6% |
| EPS | $-0.16 | $-0.09 | $-0.15 | $-0.11 | $-0.08 |
Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops AffiDX SARS-CoV-2 lateral flow rapid antigen tests, as well as Affimer reagents for third party products; and novel cancer immunotherapies combining proprietary platforms. The company has a research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein alpha; drug development collaboration with LG Chem Life Sciences; partnership with Tufts University School of Medicine for developing Affimer drug conjugate therapies; licensing agreement with POINT Biopharma Inc. for the development of tumour activated radiopharmaceuticals; and drug development partnership with AffyXell to develop engineered mesenchymal stem cells to treat autoimmune diseases. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.
Visit WebsiteEarnings History & Surprises
AVCTFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 25, 2026 | — | — | — | — |
Q3 2025 | Sep 30, 2025 | — | $-0.06 | — | — |
Q3 2024 | Sep 30, 2024 | — | $-0.05 | — | — |
Q2 2024 | Apr 30, 2024 | — | $-0.06 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.05 | — | — |
Q4 2022 | Dec 31, 2022 | $-0.06 | $-0.14 | -134.5% | ✗ MISS |
Q2 2022 | Jun 30, 2022 | — | $-0.04 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.09 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.06 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.07 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.05 | — | — |
Q4 2019 | Dec 30, 2019 | — | $-0.05 | — | — |
Q3 2019 | Jul 31, 2019 | — | $-0.05 | — | — |
Q1 2019 | Jan 31, 2019 | — | $-0.06 | — | — |
Q3 2018 | Jul 31, 2018 | — | $-0.10 | — | — |
Q1 2018 | Jan 31, 2018 | — | $-0.09 | — | — |
Q3 2017 | Jul 31, 2017 | — | $-0.06 | — | — |
Q1 2017 | Jan 31, 2017 | — | $-0.06 | — | — |
Q3 2016 | Jul 31, 2016 | — | $-0.06 | — | — |
Q1 2016 | Jan 31, 2016 | — | $-0.04 | — | — |
Latest News
Frequently Asked Questions about AVCTF
What is AVCTF's current stock price?
What is the analyst price target for AVCTF?
What sector is Avacta Group Plc in?
What is AVCTF's market cap?
Does AVCTF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to AVCTF for comparison